

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
11 May 2023 (11.05.2023)



(10) International Publication Number  
**WO 2023/079294 A1**

(51) International Patent Classification:

C07D 237/30 (2006.01) C07D 471/04 (2006.01)  
C07D 401/06 (2006.01) C07D 498/04 (2006.01)  
C07D 403/06 (2006.01) A61K 31/502 (2006.01)  
C07D 405/06 (2006.01) A61P 3/00 (2006.01)  
C07D 405/14 (2006.01) A61P 7/00 (2006.01)  
C07D 413/06 (2006.01) A61P 37/00 (2006.01)  
C07D 417/06 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/GB2022/052781

(22) International Filing Date:

04 November 2022 (04.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21206793.8 05 November 2021 (05.11.2021) EP  
21216843.9 22 December 2021 (22.12.2021) EP  
22177827.7 08 June 2022 (08.06.2022) EP

(71) Applicant: **SITRYX THERAPEUTICS LIMITED**  
[GB/GB]; 101 Bellhouse Building, Magdalen Centre, The  
Oxford Science Park, Oxford OX4 4GA (GB).

(72) Inventors: **COUSIN, David**; c/o Sygnature Discovery  
Limited, The Discovery Building Biocity, Pennyfoot Street,  
Nottingham Nottinghamshire NG1 1GR (GB). **BARBA,**  
**Oscar**; c/o Stryx Therapeutics Limited, 101 Bellhouse  
Building, Magdalen Centre, The Oxford Science Park, Ox-  
ford OX4 4GA (GB).

(74) Agent: **KINCH, Alison** et al.; Sagittarius IP, Marlow In-  
ternational, Parkway, Marlow Buckinghamshire SL7 1YL  
(GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS



(57) Abstract: The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: wherein R<sup>A</sup>, R<sup>B</sup>, R<sup>C</sup> and R<sup>D</sup>, X, Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, Z<sup>1</sup>, Z<sup>2</sup> and m are as defined herein.